![](/img/cover-not-exists.png)
Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck: An EORTC New Drug Development Group Study
F. Duffaud, M. Borner, P. Chollet, J.B. Vermorken, J. Bloch, M. Degardin, F. Rolland, C. Dittrich, B. Baron, D. Lacombe, P. FumoleauVolume:
40
Year:
2004
Language:
english
Pages:
2753
DOI:
10.1016/j.ejca.2004.08.024
File:
PDF, 248 KB
english, 2004